Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Market Potential | Explore Mereo's position in the $1B+ osteogenesis imperfecta market, with no approved targeted therapies in the EU, presenting significant growth opportunities |
Catalysts Ahead | Key milestones include Phase 2 OI data in H2 2024, Phase 3 interim readouts, and alvelestat Phase 3 initiation. Average price target: $7.50 |
Financial Runway | With $48.7M cash balance, Mereo is funded into 2026, excluding potential partnerships. Analysts project $750M+ revenue opportunity for setrusuma |
Rare Disease Pionee | Mereo Biopharma's setrusumab and alvelestat show promise in addressing unmet needs in osteogenesis imperfecta and AATD-associated lung disease |
Metrics to compare | MREO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMREOPeersSector | |
---|---|---|---|---|
P/E Ratio | −13.7x | −5.6x | −0.7x | |
PEG Ratio | 0.48 | −0.26 | 0.00 | |
Price / Book | 8.6x | 1.9x | 2.6x | |
Price / LTM Sales | 620.5x | 17.6x | 3.2x | |
Upside (Analyst Target) | 72.1% | 106.1% | 46.5% | |
Fair Value Upside | Unlock | 25.0% | 9.3% | Unlock |